Company

Bank

Analyst

Coverage

Opinion

Wk chg

5/4 cls

Actelion Ltd. (SIX:ATLN)

UBS

Guillaume van Renterghem

Price target

Buy

18%

CHF39.90

van Renterghem raised his target to CHF61 from CHF46 after macitentan met the primary endpoint in the Phase III SERAPHIN trial to treat pulmonary arterial hypertension (PAH) (see B16). Based on discussions with PAH experts, he believes the compound's morbidity and mortality benefit will "capture" at least 50% of new PAH patients receiving endothelin receptor antagonists, which could translate into CHF2.4B ($2.6B) in sales by 2025. Actelion plans to submit regulatory applications for macitentan to treat PAH, including an NDA to FDA, in 4Q12.

Biogen Idec Inc. (NASDAQ:BIIB)

Deutsche Apotheker

Robyn Karnauskas

Price target

Buy

-2%

$130.97

Jefferies

Thomas Wei

Price target

Buy